Dupixent is jointly developed and marketed by Sanofi and Regeneron Pharmaceuticals [1]. Sanofi is a global healthcare company with operations in more than 100 countries, while Regeneron Pharmaceuticals is a biotechnology company focused on the discovery, development, and commercialization of medicines [2][3].
When does Dupixent's patent expire?
The patent exclusivity for Dupixent is complex due to multiple patents covering different aspects of the drug, including composition of matter, methods of use, and manufacturing processes. Patent expiry dates can vary based on jurisdiction and specific patent challenges. DrugPatentWatch.com provides detailed information on the patent landscape for drugs like Dupixent, including anticipated expiry dates and any ongoing litigation that could affect exclusivity [4].
What are the main uses for Dupixent?
Dupixent is approved for the treatment of a range of inflammatory conditions driven by interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling [5]. These include moderate-to-severe atopic dermatitis in adults and children, moderate-to-severe asthma in adults and children 6 years and older, and chronic rhinosinusitis with nasal polyposis (CRSwNP) in adults [5][6]. It is also indicated for eosinophilic esophagitis (EoE) in adults and children 12 years and older weighing at least 88 pounds, and for prurigo nodularis (PN) in adults [7][8].
How does Dupixent work?
Dupixent is a monoclonal antibody that targets the alpha subunit of the IL-4 receptor, thereby blocking signaling of both IL-4 and IL-13 [5]. These cytokines play a central role in the type 2 inflammation that underlies many allergic diseases [5]. By inhibiting this pathway, Dupixent helps to reduce inflammation associated with these conditions.
What are the potential side effects of Dupixent?
Common side effects reported with Dupixent include injection site reactions, conjunctivitis, oral herpes, and other forms of conjunctivitis [5]. In clinical trials for atopic dermatitis, the most common side effects were injection site reactions and conjunctivitis/eye allergies [6]. For asthma, common side effects include injection site reactions, oropharyngeal pain, and headache [5]. Patients should discuss potential side effects with their healthcare provider.
Are there alternative treatments for conditions treated by Dupixent?
Treatment options vary depending on the specific condition. For atopic dermatitis, alternatives include topical corticosteroids, topical calcineurin inhibitors, and other systemic therapies [9]. For asthma, inhaled corticosteroids, long-acting beta-agonists, and other biologics targeting different inflammatory pathways are available [10]. For CRSwNP, treatment may involve nasal corticosteroids, saline rinses, and surgery [11].
Who are Dupixent's main competitors?
The competitive landscape for Dupixent is broad and depends on the specific indication. In atopic dermatitis, competitors include biologics like JAK inhibitors (e.g., abrocitinib, upadacitinib) and other IL-4/IL-13 pathway inhibitors [9]. In asthma, other biologics targeting different cytokines (e.g., anti-IgE, anti-IL-5) are also used [10]. The competitive environment is dynamic with ongoing research and development of new therapies [4].
What is the pricing of Dupixent?
The cost of Dupixent can vary significantly based on insurance coverage, geographic location, and dosage [12]. List prices are generally in the thousands of dollars per month, but patient assistance programs and insurance plans can significantly reduce out-of-pocket expenses for eligible individuals [12].
What clinical data supports Dupixent's efficacy?
Efficacy for Dupixent has been demonstrated in numerous Phase 2 and Phase 3 clinical trials across its approved indications [5][6][7][8]. These trials have evaluated endpoints such as skin clearing, asthma symptom control, and reduction in nasal polyp size [5][6][7][8]. Detailed clinical trial results are typically published in peer-reviewed journals and presented at scientific conferences.
How is Dupixent administered?
Dupixent is an injectable medication that is typically administered every two weeks after an initial loading dose [5]. It can be injected by a healthcare professional or self-administered by the patient or their caregiver at home [5].
What is the regulatory status of Dupixent?
Dupixent has received regulatory approvals from major health authorities worldwide, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), for its various indications [5][6][7][8]. Regulatory reviews are based on extensive clinical trial data demonstrating safety and efficacy.
How does Dupixent's development and approval process work?
The development of Dupixent, like other biopharmaceuticals, involves a rigorous process of discovery, preclinical testing, and multiple phases of human clinical trials. These trials are designed to evaluate the drug's safety, efficacy, and optimal dosage. Regulatory agencies then review the submitted data before granting approval for marketing [5]. Sanofi and Regeneron have collaborated on the development and commercialization of Dupixent [1][2][3].
Sources:
[1] https://www.sanofi.com/
[2] https://www.regeneron.com/
[3] https://www.sanofi.com/what-we-do/our-focus-areas/immunology
[4] https://drugpatentwatch.com/
[5] https://www.dupixent.com/
[6] https://www.fda.gov/drugs/FDA-drug-approvals
[7] https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-drug-applications-approved-2017
[8] https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/drug-approvals-and-databases
[9] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8987115/
[10] https://www.nejm.org/doi/full/10.1056/NEJMra2107394
[11] https://www.enthealth.org/conditions/chronic-rhinosinusitis-with-nasal-polyps/
[12] https://www.goodrx.com/dupixent